Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings.
During one year of treatment with oral contraceptives containing 30 micrograms ethinylestradiol and 150 micrograms desogestrel (EE/DG) or 30 micrograms EE and 75 micrograms gestodene (EE/GSD), the serum concentrations of EE, 3-keto-desogestrel (KDG) and GSD were determined on day 1, 10 and 21 of the 1st, 3rd, 6th and 12th cycle. The areas under the time-versus-concentration curves were calculated from the levels before and 0.5, 1, 1.5, 2, 3, 4 and 24 hours after intake of a tablet. There were large intra- and interindividual variations both revealing coefficients of variation (C.V.) between 25% and 80% (EE),, 30% and 50% (KDG) and 30% and 65% (GSD). During each cycle, the EE levels increased significantly between day 1 and 10 by 70% on average reaching a steady-state, while the progestogen concentrations rose by 100% (KDG) and 150% (GSD) up to a steady-state between day 10 and 21. After reaching the steady-state, the C.V. were generally lower. The ratios between the levels of EE and the progestogens showed still higher variations indicating different influences on the estrogen and progestogen component. There was no correlation between the steroid levels and weight, height or age. In spite of the large intraindividual variations, most of the women showed a distinct pattern of the levels of EE and the progestogens throughout the year of treatment indicating a genetic or acquired predisposition. The difference in the average AUC of EE, KDG and GSD between the women was 300% at most. During the first cycle of treatment with EE/DG and EE/GSD, about half of the women recorded intermenstrual bleedings which decreased thereafter. There was no relation between the occurrence of irregular bleedings and the average serum levels of EE and the progestogens of the individual women, neither during the first cycle nor during the whole treatment period of 12 cycles. It is concluded that spottings or breakthrough bleedings during treatment with oral contraceptives are not dependent on a distinct pattern of the serum levels of EE and the progestogen.
Jung-Hoffmann
C
C
Division of Gynecological Endocrinology, J.W. Goethe-University, Division of Gynecological Endocrinology, Department of Obstetrics and Gynecology, J.W. Goethe-University, Frankfurt, FRG.
Kuhl
H
H
D000293:Adolescent; D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000378:metabolism*; D017135:Desogestrel; D004997:Ethinyl Estradiol / Q000097:blood*; D005260:Female; D006801:Humans; D015999:Multivariate Analysis; D009652:Norpregnenes / Q000097:blood*; D045167:Progesterone Congeners / Q000378:metabolism*; D014592:Uterine Hemorrhage / Q000139:chemically induced*
D003277:Contraceptives, Oral, Combined; D009652:Norpregnenes; D045167:Progesterone Congeners; C033273:Gestodene; C044815:etonogestrel; D004997:Ethinyl Estradiol; D017135:Desogestrel